Neuroimaging findings of common types of neurodegenerative dementias

doi:10.16352/j.issn.1001-6325.2024.12.1741

Abstract

Abstract: Neurodegenerative dementias are a group of clinical syndromes manifested with impairment of cognitive functions with various pathological etiologies. Neuroimaging along with clinical presentations can make etiological diagnoses and support differentiate diagnosis of various dementias. In this article, we briefly introduced the MRI, PET and SPECT differential patterns in the three most common neurodegenerative dementias including Alzheimer's disease, frontotemporal lobe dementia and Lewy body dementia.

Key words: neuroimaging, positron emission tomography, Alzheimer's disease, frontotemporal dementia, Lewy body dementia

CLC Number:

LI Qijun, WANG Junshan, YUAN Jing, CUI Ruixue. Neuroimaging findings of common types of neurodegenerative dementias[J]. Basic & Clinical Medicine, 2024, 44(12): 1741-1745.

References

[1]Wilbur J. Dementia: dementia types[J]. FP Essent, 2023, 534:7-11.
[2]de Souza LC, Hosogi ML, Machado TH, et al. Diagnosis of frontotemporal dementia: recommendations of the cientific epartment of ognitive eurology and aging of the Brazilian academy of neurology[J]. Dement Neuropsychol, 2022, 16:40-52.
[3]Chiu SY, Bowers D, Armstrong MJ. Lewy body dementias: controversies and drug development[J]. Neurotherapeutics, 2022, 19:55-67.
[4]Ward J, Ly M, Raji CA. Brain PET imaging: frontotemporal dementia[J]. PET Clin, 2023, 18:123-133.
[5]Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer's disease[J]. Lancet, 2021, 397:1577-1590.
[6]Boeve BF, Boxer AL, Kumfor F, et al. Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerations[J]. Lancet Neurol, 2022, 21:258-272.
[7]Altomare D, Rivolta J, Libri I, et al. Neuropsychiatric symptoms in frontotemporal dementia: more than just noise[J]? J Alzheimers Dis, 2024, 98:133-144.
[8]Mohanty R, Ferreira D, Nordberg A, et al. Associations between different tau-PET patterns and longitudinal atrophy in the Alzheimer's disease continuum: biological and methodological perspectives from disease heterogeneity[J]. Alzheimers Res Ther, 2023, 15:80-85.
[9]Banerjee D, Muralidharan A, Hakim Mohammed AR, et al. Neuroimaging in dementia: a brief review[J]. Cureus, 2020, 12:e8682.doi:10.7759/cureus.8682.
[10]Constant AB, Basavaraju R, France J, et al. Longitudinal patterns of cortical atrophy on MRI in patients with Alzheimer disease with and without Lewy body pathology[J]. Neurology, 2022, 99: e1843-e1852.
[11]Pérez-Millan A, Borrego-Écija S, Falgàs N, et al. Cortical thickness modeling and variability in Alzheimer's disease and frontotemporal dementia[J]. J Neurol, 2024, 271:1428-1438.
[12]Jiskoot LC, Panman JL, Meeter LH, et al. Longitudinal multimodal MRI as prognostic and diagnostic biomarker in presymptomatic familial frontotemporal dementia[J]. Brain, 2019, 142:193-208.
[13]Edison P, Archer HA, Hinz R, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [¹¹C]PIB and [¹⁸F]FDG PET study[J]. Neurology, 2007, 68:501-508.
[14]Gupta V, Verma R, Ranjan R, et al. Metabolic imaging patterns in posterior cortical atrophy and Lewy body dementia[J]. Nucl Med Commun, 2019, 40:1275-1282.
[15]Bonakdarpour B, Takarabe C. Brain networks, clinical manifestations, and neuroimaging of cognitive disorders: the role of computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), and other advanced neuroimaging tests[J]. Clin Geriatr Med, 2023, 39:45-65.
[16]Brier MR, Gordon B, Friedrichsen K, et al. Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease[J]. Sci Transl Med, 2016, 8: 338ra66. doi: 10.1126/scitranslmed.aaf2362.
[17]La Joie R, Visani AV, Baker SL, et al. Prospective longitudinal atrophy in Alzheimer's disease correlates with the intensity and topography of baseline tau-PET[J]. Sci Transl Med, 2020, 12: eaau5732. doi:10.1126/scitranslmed.aau5732.
[18]Yoo HS, Chung SJ, Kim SJ, et al. The role of ¹⁸F-FP-CIT PET in differentiation of progressive supranuclear palsy and frontotemporal dementia in the early stage[J]. Eur J Nucl Med Mol Imaging, 2018, 45:1585-1595.
[19]Xiang J, Tao Y, Xia Y, et al. Development of an α-synuclein positron emission tomography tracer for imaging synucleinopathies[J]. Cell, 2023, 186:3350-3367.
[20]Zhang J, Wang J, Xu X, et al. In vivo synaptic density loss correlates with impaired functional and related structural connectivity in Alzheimer's disease[J]. J Cereb Blood Flow Metab, 2023, 43:977-988.
[21]Kantarci K, Lowe VJ, Chen Q, et al. β-Amyloid PET and neuropathology in dementia with Lewy bodies[J]. Neurology, 2020, 94:e282-e291.
[22]Diaz-Galvan P, Przybelski SA, et al. Plasma biomarkers of Alzheimer's disease in the continuum of dementia with Lewy bodies[J]. Alzheimers Dement, 2024,20:2485-2496.
[23]Li Q, Wang J, Cui R, et al. Identifying mixed dementia with Lewy bodies and Alzheimer disease using multitracer PET imaging: a case study[J]. Clin Nucl Med, 2024, 49:364-365.
[24]Kas A, Rozenblum L, Pyatigorskaya N. Clinical value of hybrid PET/MR imaging: brain imaging using PET/MR imaging[J]. Magn Reson Imaging Clin N Am, 2023, 31:591-604.
[25]Lee J, Renslo J, Wong K, et al. Current trends and applications of PET/MRI hybrid imaging in neurodegenera-tive diseases and normal aging[J]. Diagnostics (Basel), 2024, 14:585. doi.org/10.3390/diagnostics14060585.